Nova Southeastern University

NSUWorks
Biology Faculty Articles

Department of Biological Sciences

4-2001

Canine and Feline Parvoviruses Can Use Human
or Feline Transferrin Receptors to Bind, Enter, and
Infect Cells
John S. L. Parker
Cornell University

William J. Murphy
National Cancer Institute at Frederick

Dai Wang
Cornell University

Stephen J. O'Brien
National Cancer Institute at Frederick, sobrien1@nova.edu

Colin R. Parrish
Cornell University

Follow this and additional works at: https://nsuworks.nova.edu/cnso_bio_facarticles
Part of the Genetics and Genomics Commons, Virology Commons, and the Zoology Commons
NSUWorks Citation
Parker, John S. L.; William J. Murphy; Dai Wang; Stephen J. O'Brien; and Colin R. Parrish. 2001. "Canine and Feline Parvoviruses Can
Use Human or Feline Transferrin Receptors to Bind, Enter, and Infect Cells." Journal of Virology 75, (8): 3896-3902.
https://nsuworks.nova.edu/cnso_bio_facarticles/212

This Article is brought to you for free and open access by the Department of Biological Sciences at NSUWorks. It has been accepted for inclusion in
Biology Faculty Articles by an authorized administrator of NSUWorks. For more information, please contact nsuworks@nova.edu.

JOURNAL OF VIROLOGY, Apr. 2001, p. 3896–3902
0022-538X/01/$04.00⫹0 DOI: 10.1128/JVI.75.8.3896–3902.2001
Copyright © 2001, American Society for Microbiology. All Rights Reserved.

Vol. 75, No. 8

Canine and Feline Parvoviruses Can Use Human or Feline
Transferrin Receptors To Bind, Enter, and Infect Cells
JOHN S. L. PARKER,1† WILLIAM J. MURPHY,2 DAI WANG,1‡ STEPHEN J. O’BRIEN,2
1
AND COLIN R. PARRISH *

Received 8 November 2000/Accepted 22 January 2001

Canine parvovirus (CPV) enters and infects cells by a dynamin-dependent, clathrin-mediated endocytic
pathway, and viral capsids colocalize with transferrin in perinuclear vesicles of cells shortly after entry (J. S. L.
Parker and C. R. Parrish, J. Virol. 74:1919–1930, 2000). Here we report that CPV and feline panleukopenia
virus (FPV), a closely related parvovirus, bind to the human and feline transferrin receptors (TfRs) and use
these receptors to enter and infect cells. Capsids did not detectably bind or enter quail QT35 cells or a Chinese
hamster ovary (CHO) cell-derived cell line that lacks any TfR (TRVb cells). However, capsids bound and were
endocytosed into QT35 cells and CHO-derived TRVb-1 cells that expressed the human TfR. TRVb-1 cells or
TRVb cells transiently expressing the feline TfR were susceptible to infection by CPV and FPV, but the parental
TRVb cells were not. We screened a panel of feline-mouse hybrid cells for susceptibility to FPV infection and
found that only those cells that possessed feline chromosome C2 were susceptible. The feline TfR gene (TRFC)
also mapped to feline chromosome C2. These data indicate that cell susceptibility for these viruses is
determined by the TfR.
phase of the cell cycle (9), and so the target organs in vivo are
those that contain actively dividing cell populations.
The pathway of viral entry into cells is only partially characterized. Both CPV and FPV can bind sialic acid on the
surface of some host cells. However, binding sialic acid does
not appear important for viral infection, as mutants unable to
bind sialic acid retain infectivity (3). CPV capsids bound a 40to 42-kDa protein when overlaid on protein blots prepared
from canine cell lysates (5), but that protein has not been
further characterized. CPV and FPV can infect feline and
mink cells, indicating that they likely share a common receptor
and infection pathway in those cells. The process of capsid
uptake involves clathrin-mediated endocytosis, and in feline or
mink cells, capsids colocalize with transferrin in a perinuclear
compartment (20). Once endocytosed into cells, capsids appear to penetrate only slowly into the cytoplasm. Anticapsid
antibodies injected into the cytoplasm of cells prevent virus
infection even 6 h after virus inoculation, suggesting that capsids still remain within endocytic compartments several hours
after uptake (32).
We report that CPV and FPV bind to the human and feline
transferrin receptors (TfRs) and use those receptors to enter
and infect cells. Microinjected or exogenously added antibodies against the TfR prevented viral infection of cells. CPV and
FPV did not bind, enter, or infect TfR-negative Chinese hamster ovary cells (TRVb cells), but they did bind, enter, and
infect TRVb-1 cells which express the human TfR and TRVb
cells transfected with the cDNA of the feline TfR. In felinemouse hybrid cells, the feline TfR gene locus (TFRC) was
mapped to feline chromosome C2 along with susceptibility to
FPV infection.

Canine parvovirus (CPV) and feline panleukopenia virus
(FPV) are important pathogens of dogs and cats. CPV is a new
virus of dogs that first appeared in 1978, having arisen as a
variant of a virus that infected cats or a related carnivore (31).
CPV and FPV are over 99% identical in DNA sequence, but
they differ in host range (29, 30). Both viruses can infect feline
and mink cells in tissue culture, but only CPV can efficiently
infect cultured canine cells (30). FPV infection of dogs is
restricted to certain cells of the bone marrow and thymus (30).
The molecular determinants of CPV host range have been
mapped to three regions on the surface of the capsid structure.
Single amino acid changes in these regions lead to loss of the
ability of CPV to infect canine, but not feline, cells (8, 19).
Mutation of residues Asn933Asp and Asn3233Asp in the
VP2 capsid protein of FPV to the corresponding amino acids
found in the VP2 protein of CPV allows that mutant to infect
dog cells (8). The surface location of these host range determinants suggests that host range may be determined by the
ability to bind a cell surface receptor or other cellular ligand (1).
During natural infections, CPV and FPV infect actively dividing cells of the lymphopoietic system and the crypt cells of
the intestine (reviewed in reference 22). Initial virus replication occurs in the oropharyngeal lymphoid tissue, and the virus
then spreads hematogenously to other lymphoid organs and
the intestine. Autonomous parvoviruses (including CPV and
FPV) can replicate only in mitotically active cells during the S
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MATERIALS AND METHODS
Cells and viruses. Feline CRFK and Norden Laboratories feline kidney
(NLFK) cells were grown in a 1:1 mixture of McCoy’s 5A and Leibovitz L15
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FIG. 1. CPV binds and enters cells expressing the human TfR. Cells were incubated with 20 g of CPV capsids per ml and 50 g of Alexa
594-conjugated human transferrin per ml for 2 h at 37°C and then washed in PBS, fixed, and immunostained for the presence of capsids.
Differential interference contrast (DIC) images (right), transferrin (Tfn) uptake (center), and capsid uptake (left) are shown. (A) Uptake of CPV
capsids and transferrin in QT35 quail cells transfected with pCB6-HuTfR (⬃50% of cells transfected). Scale bar, 50 m. (B) Uptake of CPV
capsids and transferrin into TRVb cells (which have no endogenous TfR expression) or into TRVb-1 cells (expressing the human TfR). Scale bar,
20 m.

media with 5% fetal bovine serum. Quail QT35 cells were grown in M-24
medium with 4% chicken serum. HeLa cells were grown in Dulbecco’s modified
Eagle medium with 10% fetal bovine serum. Chinese hamster ovary-derived
TRVb and TRVb-1 cells (16) were grown in Ham’s F-12 medium with 10% fetal
bovine serum, TRVb-1 cells being grown in the presence of 400 g of Geneticin
per ml.
CPV-d and FPV-b isolates were derived from infectious plasmid clones by
transfection of NLFK cells (21), and the viruses were passaged fewer than four
times before use in these studies. To prepare capsids, viruses were propagated in
NLFK cells; the capsids were concentrated by polyethylene glycol precipitation;
and then full capsids were purified in sucrose gradients, dialyzed against 20 mM
Tris HCl (pH 7.5), and stored at 4°C.
Infection assays and antibody treatments. For all infections, a multiplicity of
infection of ⬃1 was used. Infected cells were detected by immunostaining with a
monoclonal antibody (MAb) against the nonstructural protein 1 (NS1) (36),
followed by a goat anti-mouse immunoglobulin G (IgG)-Alexa 488 secondary
conjugate (Molecular Probes, Eugene, Oreg.), or Texas Red-conjugated antiNS1 IgG was used directly. Cells were fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS) for 10 min and then permeabilized with 0.1%
Triton X-100 in PBS with 1% bovine serum albumin (permeabilization buffer).
All antibody incubations were carried out in permeabilization buffer for 45 min
at room temperature.
To examine the effect of a polyclonal anti-human TfR on infection by CPV and
FPV, HeLa or TRVb-1 cells were inoculated with CPV or FPV at a multiplicity

of infection of 1, with titers being determined by 50% tissue culture infective
dose assay in NLFK cells (19). A 1:500 dilution of sheep anti-human TfR (33)
was added to the cells either at the time of virus inoculation or 2 h later and
remained in the culture throughout the incubation. After 18 h of incubation at
37°C, the cells were fixed and permeabilized; infected cells were detected by
staining with Texas Red–anti-NS1. The percentage of cells infected was compared to the average infection of untreated cells.
To define the role of the feline TfR in virus infection and entry, antibody
H68.4 (Zymed Laboratories Inc., South San Francisco, Calif.) against the cytoplasmic domain of the TfR (35) (anti-TfR-cyt) was injected into the cytoplasm of
cells at various times around the time of virus inoculation. The H68.4 antibody
was prepared against the human TfR and recognizes a peptide common to many
species of TfRs, including the feline and canine receptors. Antibody 12CA5 IgG
against an influenza virus hemagglutinin epitope was injected into control cells.
The IgG antibodies were dialyzed against PBS, and then ⬃4 pl of antibody at 3
mg/ml was injected into CRFK cells either 2 h before or 4 or 7 h after inoculation
with virus. The cells were then incubated for 24 h before fixing and staining for
the viral NS1 protein as described above. To examine effects on capsid uptake,
cells injected with anti-TfR-cyt or antihemagglutinin IgG were incubated for 2 h
at 37°C and then incubated with 20 g of CPV full capsids per ml in Dulbecco’s
modified Eagle medium with 1% bovine serum albumin for 2 h at 37°C. The cells
were then washed in PBS, fixed in 4% paraformaldehyde in PBS, and permeabilized. The injected IgG was detected with goat anti-mouse IgG-Alexa 594
(Molecular Probes), while virus was detected with a rabbit polyclonal serum
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against intact CPV capsids followed by a goat anti-rabbit IgG-Alexa 488 conjugate (Molecular Probes).
Cloning and expression of the TfR genes. cDNA was prepared from feline liver
mRNA and used in a PCR to amplify the TfR gene in two fragments using the
Access reverse transcriptase PCR system (Promega, Madison, Wis.). Gene-specific primer pairs ([i] 5⬘-TCTAGATTAAAACTCATTGTCAATATCCC-3⬘ and
5⬘-CAGAAAAGGTTGCAAATGC-3⬘; [ii] 5⬘-ATATGGGTCACCTGTTCCCA
GATGGGCAT-3⬘ and 5⬘-CTCGAGGCCGCCACGGTGTGGCAGTTCAGA
ATGATGGAT-3⬘) were used in PCR. The intact cDNA was then cloned into
the vector pcDNA3.1(⫺) (Invitrogen, San Diego, Calif.) for expression. The
gene sequence was determined using automated sequencing.
The human TfR gene was expressed from the plasmid pCB6-HuTfR (24).
TRVb or QT35 cells seeded at a density of 2.5 ⫻ 102 cells per cm2 in 9.6-cm2
wells containing glass coverslips were transfected with 2 g of DNA using 6 l of
Lipofectamine (Life Technologies, Inc., Bethesda, Md.) according to the manufacturer’s directions. Twenty-four hours after transfection, the cells were
washed and incubated in Dulbecco’s modified Eagle medium with 1% bovine
serum albumin for 30 min at 37°C. The cells were then incubated with 20 g of
purified full virus per ml and 50 g of Alexa 594-labeled human transferrin
(Molecular Probes) per ml for 2 h at 37°C. Following virus and transferrin
uptake, the cells were fixed and permeabilized as described above. Capsids were
detected with anticapsid MAb A3B10, followed by a goat anti-mouse IgG-Alexa
488 conjugate (Molecular Probes). Coverslips were mounted on slides with
ProLong antifade agent (Molecular Probes), and confocal sections were collected with an Olympus Fluoview scanning confocal microscope using 480-nm
and 594-nm cutoff filters. Images were further processed in Adobe Photoshop to
enhance contrast and brightness. For flow cytometry, the cells were suspended by
treatment with nonenzymatic dissociation reagent (Sigma, St. Louis, Mo.) and
then fixed, permeabilized, and stained for TfR expression with anti-TfR-cyt
followed by goat anti-mouse–R-phycoerythrin conjugate (Jackson Immunore-

RESULTS
In preliminary studies, we observed that canine and mink
cells transiently overexpressing the human TfR appeared to
bind and endocytose more CPV capsids than did control plasmid-transfected cells or nontransfected cells (results not
shown). Therefore, to examine the role of the TfR in virus
binding and uptake, we expressed the human TfR or a control
plasmid in quail QT35 cells. CPV capsids did not detectably
bind to or enter nontransfected QT35 cells or cells transfected
with a control plasmid, but they were bound to and taken up to
high levels in QT35 cells expressing the human TfR (Fig. 1A).
In addition, CPV capsids did not bind or enter TRVb cells,
which do not express endogenous TfR, but they efficiently
bound to TRVb-1 cells that stably expressed the human TfR
(16) (Fig. 1B), as well as to human HeLa cells (data not
shown). The TRVb cells and both the nontransfected and
human TfR-expressing QT35 cells were not susceptible to infection by CPV or FPV (data not shown). In contrast, the
human TfR-expressing TRVb-1 cells and HeLa cells were susceptible to infection by both CPV and FPV (Fig. 2). Infection
of TRVb-1 and HeLa cells was blocked when antibodies
against the human TfR were added to those cells at the time of
virus inoculation but not when the antibodies were added 2 h
later (Fig. 2).
The anti-human TfR polyclonal serum did not recognize the
feline TfR. We therefore examined the effects of microinjection of an antibody which recognized the cytoplasmic tail of the
feline TfR (anti-TfR-cyt) on CPV infection and uptake. Injecting anti-TfR-cyt into the cytoplasm of feline CRFK cells 2 h
before virus inoculation rendered them almost completely resistant to CPV infection (Fig. 3A). In addition, the injected
cells were significantly less susceptible when the antibody was
injected at 4 but not 7 h after virus inoculation (Fig. 3A). The
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FIG. 2. Treatment of HeLa and TRVb-1 cells with polyclonal antihuman TfR inhibits infection by CPV and FPV. HeLa or TRVb-1 cells
were inoculated with CPV or FPV (multiplicity of infection of 1 as
assayed on NLFK cells). A 1:500 dilution of sheep anti-human TfR
(anti-TR) (13) was added to the cells either at the time of virus
inoculation or 2 h later, and then that was left in the culture throughout the experiment. After 18 h of incubation, cells were fixed and
permeabilized, and then the infected cells were stained with a Texas
Red-conjugated MAb raised against NS1. The percentage of infected
cells was normalized to the average infection of untreated cells. The
averages and standard deviations of the percentages of infected control
(quadruplicate wells, minimum of 1,000 cells counted per well) are
shown. TRVb cells, which do not express the TfR, were not susceptible
to CPV or FPV infection (results not shown).

search, Rockville, Md.) and stained for cell-associated capsids with a rabbit
anti-CPV antibody followed by goat anti-rabbit–Alexa 488 conjugate (Molecular
Probes). Isotype or prebleed controls and singly stained samples were used to
compensate for bleed-through fluorescence in each channel. Data were collected
with a Becton Dickinson (San Jose, Calif.) FACScalibur flow cytometer and
analyzed using CellQuest software (Becton Dickinson).
Expression of the feline TfR in TRVb cells was detected by uptake of ironloaded canine transferrin. Uptake assays were the same as described above for
human transferrin, but internalized canine transferrin was detected with a rabbit
polyclonal anti-canine transferrin antibody (kind gift of G. Apodaca, University
of Pittsburgh) followed by a goat anti-rabbit–Alexa 594 conjugate. These assays
allowed us to monitor both TfR expression and the degree of virus infection.
Mapping virus susceptibility and the TfR gene in mouse-feline hybrid cells.
Mouse ⫻ cat somatic hybrid cell lines that contain segregated feline chromosomes in different combinations (18) were inoculated with FPV at a multiplicity
of infection of 0.1. Forty-eight hours later, low-molecular-weight DNA recovered
from cells was tested for viral replicative-form DNA and single-stranded DNA by
Southern blot analysis (8). The discordance between the presence of each feline
chromosome and the cell susceptibility to FPV infection was calculated.
Radiation hybrid chromosomal mapping of the feline TfR gene (TFRC) was
performed as described by Murphy et al. (17). Primers specific for the feline TfR
gene were prepared (5⬘-CTGGCTCTCACACTCTGTCA-3⬘ and 5⬘-CCCAAAT
GTCACCAGAGAGG-3⬘). DNA prepared from 93 clones of a feline-mouse
5,000-rad-radiation hybrid cell panel was tested using PCR for the presence or
absence of the feline TfR gene. The results obtained allowed the gene to be
positioned onto the C2 framework as described previously (17). The corresponding human chromosome 3 and chromosome 21 conserved segments were derived
from the Genebridge-4-based maps in the Gene Map ’99 radiation hybrid map
database (www.ncbi.nlm.nih.gov/genemap).
Nucleotide sequence accession number. The nucleotide sequence of the TfR
gene was deposited in GenBank under accession no. AF276984.
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FIG. 3. Cytoplasmic injection of an antibody against the cytoplasmic domain of the TfR (anti-TfR-cyt) inhibits CPV infection in feline cells.
(A) Cells were injected with anti-TfR-cyt (Anti-TfR-cyt inj.) or a control IgG against the influenza virus hemagglutinin epitope (Control inj.) 2 h
before virus inoculation or 4 or 7 h after inoculation and then incubated for a total infection time of 18 h. Cells were fixed and stained for the viral
NS1 protein as a marker of infection. The percentages of the IgG-injected cells that became infected were compared to those of the noninjected
cells in the same experiment. (B) Intracytoplasmic injection of anti-TfR-cyt antibodies but not of control IgG changes the morphology and
distribution of virus-containing endosomes in cells. Cells were injected 2 h prior to adding CPV capsids (20 g/ml) and then incubated for 1 h at
37°C. The cells were then fixed and permeabilized, and the injected antibody was detected with goat anti-mouse IgG-Alexa 594 conjugate (red).
Capsids were detected with a Cy-2-conjugated MAb against CPV (green). Scale bar, 20 m.

anti-TfR-cyt injected 2 h prior to the virus inoculation did not
prevent viral endocytosis, but the virus-containing vesicles in
the anti-TfR-cyt-injected cells were larger and more widely
dispersed within the cytoplasm than were virus-containing vesicles in noninjected cells (Fig. 3B). Injection of a control IgG
had no effect on either virus infection or the size and distribution of virus-containing vesicles compared to those for noninjected cells (Fig. 3).
We inoculated feline-mouse hybrid cells that contain different known combinations of feline chromosomes with FPV and
examined the cells for susceptibility to infection. The presence
of feline chromosome C2 in a hybrid cell correlated most
closely with susceptibility to infection (Fig. 4A). TFRC was
mapped to a conserved centromeric region of feline chromosome C2 by analysis of the DNA from a 5,000-rad-radiation
hybrid panel of 93 clones (Fig. 4B).
We cloned the feline TfR gene by reverse transcriptase
PCR. The translated sequence of the feline TfR cDNA was 80
and 76% identical to the sequences of the human and Chinese
hamster TfRs, respectively. CPV and FPV capsids bound efficiently to TRVb cells expressing the feline TfR but not to cells
transfected with a control plasmid (Fig. 5A). To determine if
the feline TfR would confer susceptibility on TRVb cells, we
inoculated feline TfR-transfected or vector control-transfected
TRVb cells with CPV or FPV. A high percentage of the feline
TfR-expressing cells became infected, while few infected cells
were observed among cells transfected with a control plasmid

(Fig. 5B). We did not detect any infected cells when nontransfected cells were inoculated.
DISCUSSION
Our finding that CPV and FPV use the TfR to attach to and
infect cells is consistent with the current knowledge of the
cellular infection pathway and of the pathogenesis of these
viruses. We have previously shown that CPV capsids enter cells
by a dynamin-dependent, clathrin-mediated endocytic process
and that they colocalize with human transferrin in perinuclear
vesicles of mink lung cells that express the human TfR (20). In
light of the findings reported here, our previous observation of
increased binding of CPV capsids to mink lung cells overexpressing the Lys443Ala (K44A) mutant of dynamin I can be
explained by increased numbers of TfRs on the cell surface, as
has been reported for the insulin receptor GLUT4 in cells
overexpressing dynamin K44A (12).
The TfR is a 90-kDa type II membrane protein that is
expressed as a homodimer with an ⬃65- to 70-residue Nterminal cytoplasmic tail, a 20-residue transmembrane sequence, and an extracellular sequence of about 680 residues
(27). Structures of the ectodomain show that it consists of
apical, helical, and protease-like domains arranged in a “butterfly” configuration (14).
The TfR is constitutively endocytosed from the plasma
membrane by clathrin-mediated endocytosis (13, 34). The nat-
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ural function of the TfR is the cellular uptake of ferric iron
bound to transferrin. The TfR-transferrin complex is delivered
to the low-pH environment of the early endosome where ferric
iron is released from transferrin. The iron-free transferrin remains bound to the receptor at low pH within endosomes until
the complex is recycled to the cell surface, where the transferrin is released from the receptor at neutral pH, allowing
iron-loaded transferrin to bind. As actively dividing cells require more iron than do nondividing cells, they express greater
numbers of TfRs on their cell surface (26). Autonomous parvoviruses can replicate only in mitotically active cells during
the S phase of cell cycle; they cannot induce cells to enter the
cell cycle (9). Therefore, by binding the TfR, CPV and FPV
can preferentially target actively dividing cells that will support
viral DNA replication. High levels of TfR are found on small
intestinal crypt cells and on actively dividing lymphoid cells,
and both of these cell types are major targets for virus replication (2, 7, 15, 25).
Natural infection by CPV and FPV occurs via the oropharyngeal route, and initial viral replication occurs in the local
oropharyngeal lymphoid tissue. Thereafter, these viruses
spread to other organs hematogenously (reviewed in reference
22). The TfR is expressed mainly on the basolateral surface of
polarized epithelial cells (10), and a previous study noted that
CPV binds preferentially to the basolateral surface of polarized canine MDCK cells (4). Thus, the expression pattern of
the TfR in epithelial cells correlates with the polarized binding
of CPV and the hematogenous spread of these viruses to the
intestinal epithelium during infection (22).
CPV and FPV did not bind, enter, or infect TfR-deficient
TRVb cells. However, CPV and FPV did bind, enter, and

infect TRVb-1 or HeLa cells, which express the human TfR on
their surface, and infection of those cells was blocked by addition of a polyclonal antiserum against the human TfR at the
time of virus inoculation. The TRVb and TRVb-1 cells are
genetically identical except for the expression of the human
TfR in TRVb-1 cells (16). Therefore, the TRVb cells possess
all of the factors required for successful virus replication except
the viral receptor. Control of virus host range and susceptibility
at the level of the cell surface receptor has been reported for
many viruses, including adenoviruses (6), coronaviruses (11),
and picornaviruses (6). Although CPV and FPV bound and
entered QT35 cells expressing the human TfR, they did not
infect those cells (unpublished data), indicating that other factors required for the later stages of infection of mammalian
cells differ in those avian cells.
MAb H68.4 (anti-TfR-cyt) binds the cytoplasmic tail of the
feline TfR (35). When added to permeabilized cells, the H68.4
antibody blocked endocytosis but did not prevent formation of
deep invaginations of the cell membrane that contained the
TfR (23). In our studies, the microinjected anti-TfR-cyt antibodies efficiently blocked cell infection by CPV (Fig. 3A). Cells
injected with anti-TfR-cyt still endocytosed capsids, but both
the morphology and location of the virus-containing vesicles
within the cytoplasm differed from those seen for noninjected
or control-injected cells (Fig. 3B). The anti-TfR-cyt may interfere with the normal trafficking of viral capsids by masking
portions of the cytoplasmic tail of the TfR that are required for
trafficking or by cross-linking the receptors. Another possibility
is that anti-TfR-cyt antibody binding to the cytoplasmic tail
disrupts virus-receptor interactions required for infection
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FIG. 4. (A) Feline chromosome C2 confers susceptibility to FPV infection on feline-mouse hybrid cells. Members of a panel of feline-mouse
somatic cell hybrids with known feline karyotypes were inoculated with FPV, and the presence of replicating viral DNA was assayed 48 h later.
The discordancy between the presence of each feline chromosome and the susceptibility of the hybrid cells to virus infection is shown. (B)
Radiation hybrid mapping of the feline TfR gene (TFRC) in a panel of feline-mouse radiation hybrids. The corresponding human chromosome
3 and 21 segments aligned to the right are derived from the Genebridge-4-based maps in the Gene Map ’99 radiation hybrid map database
(www.ncbi.nlm.nih.gov/genemap). Numbers at the ends of each human conserved segment represent map positions of the most distal markers. A
scale bar is shown to the lower right (cR, centiray).
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transfer FPV susceptibility to dog cells, indicating that the
block to canine cell infection by FPV is likely due to the
specific lack of a functional receptor. We are currently examining whether differences in the feline and canine TfRs determine virus susceptibility and the host range of these viruses.
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FIG. 5. Feline TfR confers virus binding and CPV and FPV susceptibility on TRVb cells. (A) TRVb cells were transfected with a
plasmid expressing the feline TfR or with a control plasmid containing
no insert (Vector). Twenty-four hours after transfection, the cells were
washed in Dulbecco’s modified Eagle medium containing 1% bovine
serum albumin and then incubated for 2 h at 37°C with 20 g of full
CPV or FPV capsids per ml in the same medium. Cells were then
harvested, fixed, and stained for virus antigen and for the TfR using
anti-TfR-cyt. Cells were analyzed by flow cytometry, and numbers in
each quadrant indicate the percentages of cells in that category. (B)
TRVb cells that were transfected as described above were inoculated
with CPV or FPV at a multiplicity of infection of 1. Representative
panels stained for infected cells are shown. Expression of the TfR was
determined by the binding of canine transferrin, and virus infection
was detected by staining for NS1 expression. The percentage of the
feline TfR-expressing TRVb cells that became infected with CPV or
FPV is shown at the top right of each panel. Scale bar, 50 m.

which occur after the capsid has been removed from the cell
surface and has entered the early endosome.
The animal host range of CPV and FPV appears to be
naturally restricted to carnivores. Although the human TfR is
used by CPV and FPV to infect TRVb-1 cells and human
HeLa cells, there is no evidence that humans are infected by
these viruses, and it is likely that many other host or viral
factors prevent CPV or FPV from efficiently infecting and
spreading between humans. The TfR appears to be a primary
determinant of cell susceptibility to CPV and FPV infection of
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